Public Company News
Futu Holdings Achieves Solid First-Quarter Growth Amid Market Volatility with 67.9% YoY Increase in Paying Clients
- Flagship trading apps moomoo and Futubull have acquired 18.1 million global users as of quarter end PALO ALTO, Calif., June 6, 2022 /PRNewswire/ -- Moomoo's parent company Futu Holdings Limited (Nasdaq: FUTU) (Futu), a leading tech-driven online brokerage and wealth management platform, r...
2022-06-06 17:59
5566
Vection Technologies Announces Metaverse Integration for Webex Meetings at Cisco LIVE 2022
News Summary: * Vection Technologies is bringing its virtual worlds creation capabilities to Webex Meetings * Webex-first solution will be previewed at Cisco Live! in Las Vegas June 12-16 LAS VEGAS, June 6, 2022 /PRNewswire/ -- Vection Technologies is collaborating with Webex by Cisco to mak...
2022-06-06 14:18
3203
Gaotu Techedu Announces First Quarter of 2022 Unaudited Financial Results
BEIJING, June 6, 2022 /PRNewswire/ -- Gaotu Techedu Inc. (NYSE: GOTU) ("Gaotu" or the "Company"), a technology-driven education company and online large-class tutoring service provider inChina, today announced its unaudited financial results for the first quarter endedMarch 31, 2022. First Quart...
2022-06-06 14:00
5265
Market update: Strong tanker market due to sanctions and high demand for oil - Concordia Maritime
GÖTEBORG, Sweden, June 6, 2022 /PRNewswire/ -- The product tanker market has strengthened significantly during April and May, with market rates at much higher levels than for both Q1 2022 and the full year 2021. At the end of May, average spot market earnings for an MR vessel (clean) was about$36...
2022-06-06 13:39
3097
CStone and Pfizer announce NMPA approval of sugemalimab in patients with unresectable stage III non-small cell lung cancer
* The National Medical Products Administration approved sugemalimab for the treatment of patients with unresectable stage III non-small cell lung cancer whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy * Sugemalimab became the first anti-PD-...
2022-06-06 13:15
4535
Poster Highlighting Phase II Clinical Study of KN026 for HER2-expressing Advanced GC/GEJ Presented at 2022 ASCO
SUZHOU, China, June 6, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK) jointly announced that data from a phase II clinical study of KN026 (HER2 bispecific antibody) monotherapy in patients with previously treated, advance...
2022-06-06 10:49
3535
Research Updates on KN046 Presented at 2022 ASCO
SUZHOU, China, June 6, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that research updates from four clinical studies of KN046 (PD-L1/CTLA-4 bispecific antibody) presented as a poster or published online at the 2022 American Society of Clinical Oncology Annual Meeting (20...
2022-06-06 09:47
3699
SocietyOne launches transaction & savings accounts powered by Westpac
SYDNEY, June 6, 2022 /PRNewswire/ -- In its first major corporate milestone
following its acquisition by MONEYME Ltd (ASX:MME), digital finance platform
SocietyOne has launched transaction and savings accounts powered by Westpac's
Banking-as-a-Service (BaaS).
2022-06-06 09:25
4213
WuXi Biologics Launches First Commercial Drug Product Facility for Pre-Filled Syringes
* WuXi Biologics offers global partners high-efficiency and high-quality manufacturing services for clinical trial and commercial supply by increasing pre-filled syringes (PFS) capacity to 17 million units per year. * WuXi Biologics has established a global manufacturing network with 9 drug p...
2022-06-06 08:30
5062
Innovent Presents Clinical Data of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
SAN FRANCISCO and SUZHOU, China, June 6, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and ...
2022-06-06 08:08
4126
Innovent Presents Clinical Data of Phase I Study for IBI351 (KRAS G12C Inhibitor) as Monotherapy for Solid Tumors at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
SAN FRANCISCO and SUZHOU, China, June 6, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and ...
2022-06-06 08:00
4174
Innovent and IASO Bio Jointly Announce the NMPA Acceptance of the New Drug Application for Equecabtagene Autoleucel for the Treatment of Relapsed and/or Refractory Multiple Myeloma
SAN FRANCISCO and SUZHOU, China, June 6, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...
2022-06-06 08:00
4062
Angel Yeast Increases New Energy Procurement in Green Push to Curb Carbon Emission
YICHANG, China, June 5, 2022 /PRNewswire/ -- Angel Yeast (en.angelyeast.com) (SH600298), a listed global yeast and yeast extract manufacturer, is glad to announce that the Company has been granted the green electricity certificate issued and certified by China Hubei Power Exchange Center and Chin...
2022-06-05 21:00
5769
JW Therapeutics Presents Latest Data of Carteyva® at 2022 ASCO Annual Meeting
SHANGHAI, June 5, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, presented the latest data of three clinical studies on Carteyva® (relmacabtagene autoleuce...
2022-06-05 18:30
5919
CStone presents updated results of anti-PD-1 antibody nofazinlimab in combination with lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC) at ASCO 2022
* Nofazinlimab in combination with lenvatinib as first-line treatment for unresectable hepatocellular carcinoma demonstrated an objective response rate of 45.0%. The median duration of response was not yet reached as of the data cutoff date (4.2 to 18.7+ months). The median progression free sur...
2022-06-05 08:02
6307
Everest Medicines' Licensing Partner Gilead Sciences Announces Positive Results from Phase 3 TROPiCS-02 Study of Trodelvy® in Heavily Pre-treated HR+/HER2- Metastatic Breast Cancer Patients
FOSTER CITY, Calif. and SHANGHAI, June 4, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announces today that its licensing partner, Gilead Sciences, Inc. (Nasdaq: GILD), reported positive results from the primary analysis of the Phase 3 TROPiCS-02 study of Trodelvy® (sacituzumab govitecan...
2022-06-04 20:30
7613
CStone presents clinical results of sugemalimab in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma via an oral abstract session at ASCO 2022
* GEMSTONE-201 is the largest registrational clinical study of an anti-PD-(L)1 antibody reported so far in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL). * Results on the primary endpoint showed that sugemalimab significantly improved objective res...
2022-06-04 08:02
8477
KT SAT to participate Communic Asia 2022 showcasing its service competitiveness
SEOUL, South Korea, June 3, 2022 /PRNewswire/ -- KT SAT, South Korea's the sole
satellite service company with its self-owned satellites, participated in
Communic Asia 2022,Asia's leading technology trade show held in Singapore Expo
from 1st to 3rd, June.
2022-06-03 14:45
14339
SCB powers its path toward digital banking leadership and new era of API-led modernized banking platforms with IBM
* SCB's continuous investment in its IT infrastructure today ensures millions of its customers nationwide can enjoy exceptional services and products. BANGKOK ,June 3, 2022 /PRNewswire/ -- SCB announced today the adoption of IBM zSystems (NYSE:IBM), bringing the highly secured, high availability...
2022-06-03 12:41
10468
XCMG Consolidates Sustainable Development with New Energy-Centric Strategies During World Environment Day 2022
XUZHOU, China, June 3, 2022 /PRNewswire/ -- XCMG (SHE:000425) has obtained the first "green license" inChina's construction crane sector in May for its XCT25PHEV hybrid crane, which is the first "true hybrid" model in the world. It was developed over the course of five years and underwent another...
2022-06-03 11:58
5930
Week's Top Stories
Most Reposted
TD Brings its Global Asset Management Businesses Under One Name
[Picked up by 1168 media titles]
2026-11-02 20:00OceanaGold Reports Third Quarter 2026 Results
[Picked up by 1129 media titles]
2026-11-05 06:52Overstory Launches Integrated AI Platform to Deliver First Living Model of Grid Risk
[Picked up by 1082 media titles]
2026-11-03 22:00Fintech OPay Raises $304 Million Ahead of NYSE Debut: NYSE Content Update
[Picked up by 1079 media titles]
2026-10-30 22:34
H.E. Ahmed Al-Khateeb, Saudi Minister of Tourism, Inaugurates Saudi Land at WTM London 2026, Reinforcing Saudi's Commitment to Global Travel Trade
[Picked up by 1067 media titles]
2026-11-04 07:31
Most Read
1B views since June: Coda and TikTok Gaming turn content into commerce
2026-11-02 09:35
59666
Airbrush Upgrades AI Image Enhancer With 16K Output and Batch Processing for Up to 50 Images
2026-11-03 02:00
54717
iQIYI Launches China's First AI Film Studio in Shanghai, with Inaugural Title "Cop in Trouble" in Production
2026-11-02 09:52
52721
Korean Derma Skincare Brand MDP+ Launches at Nordstrom
2026-11-03 00:30
22167
Lorikeet Dreamweaver enables businesses to give every customer an AI account manager
2026-11-04 22:00
17491